Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA17 in Relapsed/Refractory Multiple Myeloma
NCT06279026Phase 1Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA-17 in multiple myeloma (MM), sponsored by PersonGen BioTherapeutics. Primary endpoints: Dose-Limiting Toxicity at 28 days and Recommended Phase 2 Dose at 1 year. Started Apr 2024; status: recruiting.
02
Drugs
UTAA-17
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06279026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06279026.